Imuran (Azathioprine)

Azathioprine is a prodrug that is metabolized to 6‑mercaptopurine, which blocks the synthesis of purine nucleotides. This inhibition limits DNA replication in rapidly dividing lymphocytes, leading to decreased proliferation of T and B cells and a consequent reduction in immune‑driven inflammation.

The appropriate dose of Imuran is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and laboratory monitoring results. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

The safety of Imuran during pregnancy and lactation has not been definitively established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician, as the drug may cross the placenta and be present in breast milk.

To order Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both Imuran (azathioprine) and mycophenolate mofetil are antimetabolite immunosuppressants, but they inhibit different enzymes in the purine synthesis pathway. Azathioprine is often used when cost considerations are paramount or when a clinician prefers its longer clinical experience, while mycophenolate may offer a more favorable side‑effect profile for some patients. Choice depends on individual patient factors and physician judgment.

Imuran tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Imuran is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity with potential liver failure, and an increased susceptibility to serious infections, including opportunistic pathogens. Patients should be monitored regularly with blood counts and liver function tests to detect these complications early.

Imuran is contraindicated in individuals with known hypersensitivity to azathioprine or any of its components, in patients with active severe infections, and in those with significant bone‑marrow failure or severe hepatic impairment. Caution is also advised for patients with a history of malignancy.